Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
Identifieur interne : 000300 ( France/Analysis ); précédent : 000299; suivant : 000301Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
Auteurs : A. Delluc [France] ; N. Limal [France] ; X. Puéchal [France] ; C. Francès [France] ; J C Piette [France] ; P. Cacoub [France]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2008-02.
English descriptors
- Teeft :
- Acad, Acad dermatol, Adalimumab, Adalimumab refutes, Alveolar lung condensations, Anakinra, Anakinra introduction, Antagonist, Antimalarial, Apoptosis, April, Arthritis rheum bourke, Azathioprine, Bernier, Biochem, Biochem pharmacol lagneaux, Bourke, Bron, Cacoub, Cacoub1, Carlier, Case report, Cell type, Centre hospitalier, Characterised, Chemoattractant, Chemokines, Clin, Clin rheumatol, Cnrs, Colchicine, Control anakinra, Corticosteroid, Costenbader, Cyclophosphamide, Cytokine, Delforge, Dense neutrophilic, Dermal, Dermatol, Dermatol dinarello, Dermatosis, Dinarello, Disease activity, Disease concepts, Disulone, Dose prednisone, Dramatic efficacy, Drug effects, Drug responses, Early induction, Egurbide, Engl, Epidermal, Epidermal staining, Erythematosus, Erythematous, Erythrocyte, Erythrocyte sedimentation rate, Experimental breast cancer agents, February, First time, France correspondence, Garmendia, Giasuddin, Good efficacy, Haematol, Haematol efficacy, Haemolysis, Histopathologic, Histopathologic evidence, Hopital, Hopital service, Hospitalier, Human breast cancer cell model, Human receptor antagonist, Hydroxychloroquine, Immortal time bias, Immunohistochemical, Immunohistochemical study, Immunosuppressive, Immunosuppressive drugs, Increase production, Inflammation, Inflammatory, Inflammatory disease, Interleukin, January, July, Kinereth, Kurzrock, Laboratory signs, Lagneaux, Lesion, Leukaemia, Lower staining, Lupus, Lymphocyte, Lymphocytic, Lymphocytic leukaemia cells, Macrophage, Major pathophysiological role, Many worlds, Marie curie paris, Martinezberriotxoa, Martirosyan, Massy, Mature neutrophils, Medecine, Mediator, Methotrexate, Natural inhibitor, Neutrophil, Neutrophilia, Neutrophilic, Neutrophilic dermatosis characterised, Nitric, Nitric oxide, Normal control subjects, Observational studies, Online, Pathological study, Pathophysiological, Pharmacoepidemiol, Pharmacoepidemiol drug, Pharmacol, Pijoan, Possible mediator, Previous studies, Prostaglandin, Pulmonary involvement, Quinolines, Radiological, Radiological remission, Randomised, Receptor, Receptor antagonist, Receptor antagonist anakinra kinereth, Recombinant, Recombinant form, Recurrent fever, Refractory, Refutes, Remission, Remodelling, Rheum, Rheumatol, Rhumatologie, Right flank, Same treatment regimen, Secrete, September, Serum levels, Severe haemolysis, Significant reduction, Skin lesions, Specific intervention, Specific neutrophil chemoattractant, Strobl, Study5, Subcutaneously, Suissa, Survival factors, Syndrome, Systemic lupus erythematosus, Tender erythematous skin lesions, Tissue remodelling, Tumour, Tumour necrosis factor, Type1, Type1 receptor, Ugarte, Universite pierre, Various functions, White blood cells.
Url:
DOI: 10.1136/ard.2006.068254
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B71
- to stream Istex, to step Curation: 001B71
- to stream Istex, to step Checkpoint: 000913
- to stream Main, to step Merge: 001A16
- to stream Main, to step Curation: 001A08
- to stream Main, to step Exploration: 001A08
- to stream France, to step Extraction: 000300
Links to Exploration step
ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
<author><name sortKey="Delluc, A" sort="Delluc, A" uniqKey="Delluc A" first="A" last="Delluc">A. Delluc</name>
</author>
<author><name sortKey="Limal, N" sort="Limal, N" uniqKey="Limal N" first="N" last="Limal">N. Limal</name>
</author>
<author><name sortKey="Puechal, X" sort="Puechal, X" uniqKey="Puechal X" first="X" last="Puéchal">X. Puéchal</name>
</author>
<author><name sortKey="Frances, C" sort="Frances, C" uniqKey="Frances C" first="C" last="Francès">C. Francès</name>
</author>
<author><name sortKey="Piette, J C" sort="Piette, J C" uniqKey="Piette J" first="J C" last="Piette">J C Piette</name>
</author>
<author><name sortKey="Cacoub, P" sort="Cacoub, P" uniqKey="Cacoub P" first="P" last="Cacoub">P. Cacoub</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1136/ard.2006.068254</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B71</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B71</idno>
<idno type="wicri:Area/Istex/Curation">001B71</idno>
<idno type="wicri:Area/Istex/Checkpoint">000913</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000913</idno>
<idno type="wicri:doubleKey">0003-4967:2008:Delluc A:efficacy:of:anakinra</idno>
<idno type="wicri:Area/Main/Merge">001A16</idno>
<idno type="wicri:Area/Main/Curation">001A08</idno>
<idno type="wicri:Area/Main/Exploration">001A08</idno>
<idno type="wicri:Area/France/Extraction">000300</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
<author><name sortKey="Delluc, A" sort="Delluc, A" uniqKey="Delluc A" first="A" last="Delluc">A. Delluc</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Limal, N" sort="Limal, N" uniqKey="Limal N" first="N" last="Limal">N. Limal</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Puechal, X" sort="Puechal, X" uniqKey="Puechal X" first="X" last="Puéchal">X. Puéchal</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Rhumatologie, Centre Hospitalier du Mans</wicri:regionArea>
<wicri:noRegion>Centre Hospitalier du Mans</wicri:noRegion>
<wicri:noRegion>Centre Hospitalier du Mans</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Frances, C" sort="Frances, C" uniqKey="Frances C" first="C" last="Francès">C. Francès</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Piette, J C" sort="Piette, J C" uniqKey="Piette J" first="J C" last="Piette">J C Piette</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cacoub, P" sort="Cacoub, P" uniqKey="Cacoub P" first="P" last="Cacoub">P. Cacoub</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2008-02">2008-02</date>
<biblScope unit="volume">67</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="278">278</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term>
<term>Acad dermatol</term>
<term>Adalimumab</term>
<term>Adalimumab refutes</term>
<term>Alveolar lung condensations</term>
<term>Anakinra</term>
<term>Anakinra introduction</term>
<term>Antagonist</term>
<term>Antimalarial</term>
<term>Apoptosis</term>
<term>April</term>
<term>Arthritis rheum bourke</term>
<term>Azathioprine</term>
<term>Bernier</term>
<term>Biochem</term>
<term>Biochem pharmacol lagneaux</term>
<term>Bourke</term>
<term>Bron</term>
<term>Cacoub</term>
<term>Cacoub1</term>
<term>Carlier</term>
<term>Case report</term>
<term>Cell type</term>
<term>Centre hospitalier</term>
<term>Characterised</term>
<term>Chemoattractant</term>
<term>Chemokines</term>
<term>Clin</term>
<term>Clin rheumatol</term>
<term>Cnrs</term>
<term>Colchicine</term>
<term>Control anakinra</term>
<term>Corticosteroid</term>
<term>Costenbader</term>
<term>Cyclophosphamide</term>
<term>Cytokine</term>
<term>Delforge</term>
<term>Dense neutrophilic</term>
<term>Dermal</term>
<term>Dermatol</term>
<term>Dermatol dinarello</term>
<term>Dermatosis</term>
<term>Dinarello</term>
<term>Disease activity</term>
<term>Disease concepts</term>
<term>Disulone</term>
<term>Dose prednisone</term>
<term>Dramatic efficacy</term>
<term>Drug effects</term>
<term>Drug responses</term>
<term>Early induction</term>
<term>Egurbide</term>
<term>Engl</term>
<term>Epidermal</term>
<term>Epidermal staining</term>
<term>Erythematosus</term>
<term>Erythematous</term>
<term>Erythrocyte</term>
<term>Erythrocyte sedimentation rate</term>
<term>Experimental breast cancer agents</term>
<term>February</term>
<term>First time</term>
<term>France correspondence</term>
<term>Garmendia</term>
<term>Giasuddin</term>
<term>Good efficacy</term>
<term>Haematol</term>
<term>Haematol efficacy</term>
<term>Haemolysis</term>
<term>Histopathologic</term>
<term>Histopathologic evidence</term>
<term>Hopital</term>
<term>Hopital service</term>
<term>Hospitalier</term>
<term>Human breast cancer cell model</term>
<term>Human receptor antagonist</term>
<term>Hydroxychloroquine</term>
<term>Immortal time bias</term>
<term>Immunohistochemical</term>
<term>Immunohistochemical study</term>
<term>Immunosuppressive</term>
<term>Immunosuppressive drugs</term>
<term>Increase production</term>
<term>Inflammation</term>
<term>Inflammatory</term>
<term>Inflammatory disease</term>
<term>Interleukin</term>
<term>January</term>
<term>July</term>
<term>Kinereth</term>
<term>Kurzrock</term>
<term>Laboratory signs</term>
<term>Lagneaux</term>
<term>Lesion</term>
<term>Leukaemia</term>
<term>Lower staining</term>
<term>Lupus</term>
<term>Lymphocyte</term>
<term>Lymphocytic</term>
<term>Lymphocytic leukaemia cells</term>
<term>Macrophage</term>
<term>Major pathophysiological role</term>
<term>Many worlds</term>
<term>Marie curie paris</term>
<term>Martinezberriotxoa</term>
<term>Martirosyan</term>
<term>Massy</term>
<term>Mature neutrophils</term>
<term>Medecine</term>
<term>Mediator</term>
<term>Methotrexate</term>
<term>Natural inhibitor</term>
<term>Neutrophil</term>
<term>Neutrophilia</term>
<term>Neutrophilic</term>
<term>Neutrophilic dermatosis characterised</term>
<term>Nitric</term>
<term>Nitric oxide</term>
<term>Normal control subjects</term>
<term>Observational studies</term>
<term>Online</term>
<term>Pathological study</term>
<term>Pathophysiological</term>
<term>Pharmacoepidemiol</term>
<term>Pharmacoepidemiol drug</term>
<term>Pharmacol</term>
<term>Pijoan</term>
<term>Possible mediator</term>
<term>Previous studies</term>
<term>Prostaglandin</term>
<term>Pulmonary involvement</term>
<term>Quinolines</term>
<term>Radiological</term>
<term>Radiological remission</term>
<term>Randomised</term>
<term>Receptor</term>
<term>Receptor antagonist</term>
<term>Receptor antagonist anakinra kinereth</term>
<term>Recombinant</term>
<term>Recombinant form</term>
<term>Recurrent fever</term>
<term>Refractory</term>
<term>Refutes</term>
<term>Remission</term>
<term>Remodelling</term>
<term>Rheum</term>
<term>Rheumatol</term>
<term>Rhumatologie</term>
<term>Right flank</term>
<term>Same treatment regimen</term>
<term>Secrete</term>
<term>September</term>
<term>Serum levels</term>
<term>Severe haemolysis</term>
<term>Significant reduction</term>
<term>Skin lesions</term>
<term>Specific intervention</term>
<term>Specific neutrophil chemoattractant</term>
<term>Strobl</term>
<term>Study5</term>
<term>Subcutaneously</term>
<term>Suissa</term>
<term>Survival factors</term>
<term>Syndrome</term>
<term>Systemic lupus erythematosus</term>
<term>Tender erythematous skin lesions</term>
<term>Tissue remodelling</term>
<term>Tumour</term>
<term>Tumour necrosis factor</term>
<term>Type1</term>
<term>Type1 receptor</term>
<term>Ugarte</term>
<term>Universite pierre</term>
<term>Various functions</term>
<term>White blood cells</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Delluc, A" sort="Delluc, A" uniqKey="Delluc A" first="A" last="Delluc">A. Delluc</name>
</region>
<name sortKey="Cacoub, P" sort="Cacoub, P" uniqKey="Cacoub P" first="P" last="Cacoub">P. Cacoub</name>
<name sortKey="Frances, C" sort="Frances, C" uniqKey="Frances C" first="C" last="Francès">C. Francès</name>
<name sortKey="Limal, N" sort="Limal, N" uniqKey="Limal N" first="N" last="Limal">N. Limal</name>
<name sortKey="Piette, J C" sort="Piette, J C" uniqKey="Piette J" first="J C" last="Piette">J C Piette</name>
<name sortKey="Puechal, X" sort="Puechal, X" uniqKey="Puechal X" first="X" last="Puéchal">X. Puéchal</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000300 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000300 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= France |étape= Analysis |type= RBID |clé= ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3 |texte= Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome }}
This area was generated with Dilib version V0.6.33. |